Triamterene Solubility and Metabolism are not Causative Factors of Triamterene Nephrolithiasis
Although the risk of passing a kidney stone during triamterene therapy is not yet fully understood1,2 there is enough evidence to suggest that deposition of triamterene and other drugs in kidney stones is a frequent occurrence3. Since our initial report on the presence of triamterene in kidney stones, only a few studies have appeared on this topic and it still remains unclear as to why triamterene is found in stones. We now report the true composition of kidney stones passed during triamterene therapy, which may help to explain why it is incorporated. Also, we will report the first data on triamterene metabolism in patients passing these stones, as well as in patients chronically using triamterene. Previously published data will also be discussed in the light of our data.
KeywordsKidney Stone Calcium Oxalate Metabolic Ratio Calcium Oxalate Crystal Drug Precipitation
Unable to display preview. Download preview PDF.
- 1.B. Ettinger, N. O. Oldroyd, and F. Sorgel,in: “Urolithiasis: Clinical and Basic Research”, L. H, Smith, W. G. Robertson, and B. Finlayson, eds., Plenum, New York (1981)Google Scholar
- 3.R. J. Reveilland and M. Daudon, in: “Urolithiasis and Related Clinical Research”, P. O. Schwüle, L. H. Smith, W. G. Robertson, and W. Vahlensieck, eds., Plenum, New York (1985).Google Scholar
- 4.W. Stüber, E. Mutschler, and D. Steinbach, Arzneim.-Forsch. 30:1158 (1980).Google Scholar
- 5.B. Grebian, H. E. Geissler, and E. Mutschler, Arzneim.-Forsch. 26:2125 (1976).Google Scholar
- 6.P. G. Werness, J. H. Bergert, and L. H. Smith, J. Lab. Clin. Invest. 99:254 (1982).Google Scholar